$MREO

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.

Law firm Holzer & Holzer announces April 6, 2026 lead plaintiff deadlines for class actions against TCPC, MREO, POM, and RARE over alleged material misstatements.

Rosen Law Firm urges MREO investors to act before April 6, 2026 deadline in securities class action alleging misleading clinical trial statements.

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC. Investors from June 2023-December 2025 eligible; lead plaintiff deadline April 2026.

Four companies face April 6, 2026 lead plaintiff deadline in shareholder lawsuits alleging disclosure violations involving valuations, clinical trials, and fraudulent promotion.

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.

Pomerantz Law Firm filed class action against $MREO after Phase 3 trial failures. Stock plummeted 87.7%. Investor deadline: April 6, 2026.

Mereo BioPharma faces class action over failed Phase 3 trials and alleged misleading statements. Investor deadline April 6, 2026.

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory management and tax credit impacts. Lead plaintiff deadline April 20, 2026.

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.

Mereo BioPharma faces securities class action for allegedly concealing failed Phase 3 trials for setrusumab. Investors have until April 6, 2026 to act.

Mereo BioPharma faces securities lawsuit alleging misrepresentations about Phase 3 trial results for setrusumab, causing investor losses.

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.

Mereo BioPharma faces securities litigation alleging it misled investors about Phase 3 clinical trial results for setrusumab, failing to disclose the trials missed primary endpoints.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.